Logo

Skyline Diagnostics

SkylineDx, NeraCare Partnering on Proteomic Test for Melanoma

The companies inked a codevelopment and licensing agreement for NeraCare's Immunoprint test for identifying high-risk early-stage melanoma patients.

SkylineDx Gains CE-IVD Mark for Melanoma Metastasis Risk Assay

The Netherlands-based firm is partnering with Belgian company Biocartis on European commercialization of the qPCR assay, which could reduce unnecessary surgeries.

SkylineDx, VIB Form Molecular Diagnostics Partnership

The partnership will focus on high-potential in vitro diagnostic opportunities for unmet medical needs for global markets.

Biocartis, SkylineDx Partner to Develop Melanoma Nodal Metastasis Risk Test

The Belgian molecular diagnostics firm also reported a 70 percent year-over-year increase in commercial cartridge volumes in the first quarter.

SkylineDx, Imperial College London, UCSD Partner to Develop Kawasaki Disease Test

The test is based on 13 genes that form a gene signature in the blood of children with Kawasaki disease, and it enables KD to be distinguished from other diseases.

Mar 24, 2020

SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological Signatures for Cancers

Mar 12, 2020

DIAMONDS Project Using New Classification Approach to Develop Rapid Infectious Disease Tests
Premium

Feb 4, 2020

SkylineDx Partners With German Hospital to Assess Multiple Myeloma Test

Sep 24, 2019

SkylineDx Partners With Mayo Clinic on Melanoma Risk Test Study Ahead of Planned US Trial
Premium

Sep 3, 2019

SkylineDx Secures $21.9M Investment

Jun 28, 2019

In Brief This Week: Invitae, Personalis, Seegene, Precipio, SkylineDx, and More

Jan 31, 2018

SkylineDx, Mayo Clinic to Develop Diagnostic Tests for Melanoma

Dec 20, 2017

Skyline Medical to Acquire Up to 25 Percent of Helomics

Apr 18, 2017

SkylineDx Develops Tool to Predict Cancer Therapies Based on Genomic Data
Premium

Oct 21, 2016

SkylineDx Follows Multiple Myeloma MDx With Collaborative Effort to Develop Therapy Selection Assay
Premium

Nov 25, 2015

SkylineDx Lands CE-IVD Mark for MMProfiler

Apr 1, 2014

SkylineDx Opens US Office to Market Multiple Myeloma Test to American Clinicians, Pharma
Premium

Sep 24, 2013

Newly Formed SkylineDx Acquires Array Tests, IP, Other Assets of Defunct Skyline Diagnostics
Premium

Jan 2, 2013

People in the News: Kurt Schmidt, Henk Viëtor
Premium

Jun 26, 2012

Skyline Dx Partners with LabPMM to Offer Array-based AML Testing Service in Europe
Premium

Sep 7, 2011

Clavis Pharma Taps Skyline Dx for Array-based Patient Selection in AML Drug Trial
Premium

Sep 6, 2011

Skyline, Clavis Partner on Biomarkers for AML Drug

Jul 26, 2011

Skyline Dx, Janssen Partner on Adverse Reaction Risk Test for Multiple Myeloma Drug
Premium

Jul 6, 2011

Skyline Dx, Janssen Partner on Companion Dx Deal

Mar 22, 2011

New Product Watch: Mar 22, 2011
Premium

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.